An economic evaluation of rosuvastatin treatment in systolic heart failure: Evidence from the CORONA trial

European Journal of Heart Failure

Volumn 12, Issue 1, 2010, Pages 66-74

  Lorgelly, Paula K ^a   Briggs, Andrew H ^a   Wedel, Hans ^b   Dunselman, Peter ^c   Hjalmarson, AKe ^d   Kjekshus, John ^e   Waagstein, Finn ^d   Wikstrand, John ^d   Jánosi, András ^f   Van Veldhuisen, Dirk J ^g   Barrios, Vivencio ^h   Fonseca, Cândida ⁱ   McMurray, John J V ^j  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^c AMPHIA HOSPITAL   (Netherlands)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f ST JOHN'S HOSPITAL   (Hungary)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h HOSPITAL RAMÓN Y CAJAL   (Spain)

ⁱ HOSPITAL DE SÃO FRANCISCO XAVIER   (Portugal)

^j UNIVERSITY OF GLASGOW   (United Kingdom)

more..

Author keywords

Cost effectiveness; Heart failure; Multinational trial; Statins

Indexed keywords

ROSUVASTATIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

AGED; CARDIOPULMONARY BYPASS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; FEMALE; FLUOROBENZENES; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL MORTALITY; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; SULFONAMIDES;

EID: 72649106603     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp172     Document Type: Article

References (21)

1. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614-1619.
2. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D'Agostino RB, Kannel WB, Murabito JM, Vasan RS, Benjamin EJ, Levy D. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002;106:3068-3072. (Pubitemid 35440290)
3. Stewart S, MacIntyre K, Capewell S, McMurray JJ. Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003;89:49-53.
4. Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail 2002;4:361-371.
5. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. BMJ 2006;333:1145.
6. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002;39:1567-1573.
7. Kjekshus J, Dunselman P, Blideskog M, Eskilson C, Hjalmarson A, McMurray JV, Waagstein F, Wedel H, Wessman P, Wikstrand J. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7:1059-1069.
8. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamensky G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357:2248-2261. (Pubitemid 350190755)
9. Department of Health. NHS reference costs 2005-2006. http://www.dh.gov. uk/en/ Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH- 062884.
10. The NHS Information Centre. Casemix Service. http://www.ic.nhs.uk/our- services/ standards-and-classifications/casemix/hrg4.
11. British Medical Association & Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ; 2006.
12. Fieller EC. Some problems in interval estimation. J R Stat Soc Series B-Statist Meth-odol 1954;16:175-185.
13. van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994;3:309-319.
14. HM Treasury. The Green Book: Appraisal and Evaluation in Central Government. London: TSO; 2007.
15. Healthcare Commission. Getting results: pathology services in acute and specialist trusts. http://www.healthcarecommission.org.uk/-db/-documents/ Pathology-final-tagged.pdf.
16. Netten A, Curtis L. Unit Costs of Health and Social Care 2006. Canterbury: Personal Social Services Research Unit, University of Kent; 2006.
17. McMurray JJ, Andersson FL, Stewart S, Svensson K, Solal AC, Dietz R, Vanhaecke J, van Veldhuisen DJ, Ostergren J, Granger CB, Yusuf S, Pfeffer MA, Swedberg K. Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2006;27:1447-1458.
18. Reed SD, Anstrom KJ, Bakhai A, Briggs AH, Califf RM, Cohen DJ, Drummond MF, Glick HA, Gnanasakthy A, Hlatky MA, O'Brien BJ, Torti FM, Tsiatis AA, Willan AR, Mark DB, Schulman KA. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J 2005;149: 434-443.
19. Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20,536 individuals. Lancet 2005;365:1779-1785.
20. Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53-72.
21. Wedel H, McMurray JJ, Lindberg M, Wikstrand J, Cleland JG, Cornel JH, Dunselman P, Hjalmarson A, Kjekshus J, Komajda M, Kuusi T, Vanhaecke J, Waagstein F. Predictors of fatal and non-fatal outcomes in the Controlled Rosu-vastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide. Eur J Heart Fail 2009;11:281-291.